Prevention of hyponatraemia and cerebral oedema by the vasopressin antagonist d/CH2/5Tyr/Et/VAVP in rats treated with pitressin tannate

Publisher Website
Google Scholar
Abstract
A rat model of the Schwartz-Bartter syndrome was created by the administration of a high dose of a long-acting vasopressin preparation (pitressin tannate) together with a forced water intake. The treatment led to water retention, hypernatriuria, marked hyponatremia (in 4-5 days) and severe cerebral edema. These changes could be prevented by the simultaneous administration of [1-(.beta.-mercapto-.beta.,.beta.-cyclopentamethylene-propionic acid),2-0-ethyltyrosine,4-valine]arginine vasopressin. This vasopressin antagonist analog might be of use in the future as an effective drug against the Schwartz-Bartter syndrome.